# Sermorelin References: The Cited GHRH(1-29) Literature

> Sermorelin references — the full cited literature behind this digest, with DOIs and PubMed links: the pediatric trial, the aging studies, the pharmacokinetics, the reviews, and the FDA and WADA record.

Every claim on this site resolves to a numbered source below, with a DOI or PubMed link.

## How to read this list

Every numbered marker in the text resolves to an entry here. Quantitative claims — doses, percentages, durations, and dates — are each tied to a specific source. Peer-reviewed studies carry a DOI and a PubMed link; the regulatory record (FDA guidance, the WADA status) is cited to its primary document. Where a finding comes from a closely related GHRH analog rather than sermorelin itself, the text says so. The full citations are on the references list below.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[7] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/
[8] Yuen KC, Biller BM, Molitch ME, Cook DM. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab. 2009;94(8):2702-2707. https://pubmed.ncbi.nlm.nih.gov/19509104/
[9] U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Guidance for Industry). 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and
[10] Coutinho LFD, De Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026. https://pubmed.ncbi.nlm.nih.gov/41880199/
[11] World Anti-Doping Agency. The Prohibited List: S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics (growth hormone secretagogues, including GHRH and its analogues, prohibited at all times). World Anti-Doping Agency. https://www.wada-ama.org/en/prohibited-list
[12] Ogilvy-Stuart AL, et al. Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone. Clin Endocrinol (Oxf). 1997;46(5):571-578. https://pubmed.ncbi.nlm.nih.gov/9231053/
[13] Thornton PL, et al. Chronic [D-Ala2]-growth hormone-releasing hormone administration attenuates age-related deficits in spatial memory. J Gerontol A Biol Sci Med Sci. 2000;55(2):B106-B112. https://pubmed.ncbi.nlm.nih.gov/10737685/
[14] Utz AL, et al. The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors. Mediators Inflamm. 2010;2010:434562. https://pubmed.ncbi.nlm.nih.gov/20150954/

---

A status-and-access ledger of the sermorelin (GHRH 1-29) record — the former approval, the 2008 commercial withdrawal, the Category 1 503A standing and the WADA S2 line each logged to source and kept distinct; no clinic behind the console, no script filled here, nothing dispensed, sourced, or sold.